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Introduction: To investigate the mechanism of action of tranexamic acid (TXA) in bleeding trauma patients, we
examined the timing of its effect on mortality. We hypothesised that if TXA reduces mortality by decreasing blood
loss, its effect should be greatest on the day of the injury when bleeding is most profuse. However, if TXA reduces
mortality via an anti-inflammatory mechanism its effect should be greater over the subsequent days.
Methods: Exploratory analysis, including per-protocol analyses, of data from the CRASH-2 trial, a randomised
placebo controlled trial of the effect of TXA on mortality in 20,211 trauma patients with, or at risk of, significant
bleeding. We examined hazard ratios (HR) and 95% confidence intervals for all-cause mortality, deaths due to
bleeding and non-bleeding deaths, according to the day since injury. The CRASH-2 trial is registered as
ISRCTN86750102 and ClinicalTrials.gov NCT00375258.
Results: The effect of TXA on mortality is greatest for deaths occurring on the day of the injury (HR all-cause
mortality = 0.83, 0.73 to 0.93). This survival benefit is only evident in patients in whom treatment is initiated within
3 hours of their injury (HR ≤3 hours = 0.78, 0.68 to 0.90; HR >3 hours = 1.02, 0.76 to 1.36). Initiation of TXA treatment
within 3 hours of injury reduced the hazard of death due to bleeding on the day of the injury by 28% (HR = 0.72, 0.60
to 0.86). TXA treatment initiated beyond 3 hours of injury appeared to increase the hazard of death due to bleeding,
although the estimates were imprecise.
Conclusions: Early administration of tranexamic acid appears to reduce mortality primarily by preventing
exsanguination on the day of the injury.Introduction
The CRASH-2 trial has shown that administration of
tranexamic acid (TXA) to bleeding trauma patients who
are within 3 hours of injury, significantly reduces death
due to bleeding (risk ratio (RR) = 0.72, 95% CI 0.63, 0.83)
and all-cause mortality, without increasing the risk of
vascular occlusive events [1,2]. Since the publication of
these results, there has been debate about the mechanism
of action of TXA in trauma patients. Several authors, ob-
serving that plasmin is pro-inflammatory, suggest that
TXA increases survival by reducing inflammation [3-7].
On the basis of results from an observational study of
TXA administration in combat casualties, the investigators
of the military application of TXA in trauma emergency* Correspondence: Ian.Roberts@lshtm.ac.uk
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unless otherwise stated.resuscitation study (MATTERS) argued that the timing
of the survival benefit with TXA suggests a mechanism
other than haemostasis and hypothesised that TXA
may attenuate the inflammatory response. Similarly,
Neapolitano et al., noting the lack of a statistically sig-
nificant difference in blood transfusion between TXA
and placebo groups state that ? it remains unclear whether
the mortality benefit from TXA is from reversal of fibrin-
olysis or whether an inflammatory or immune modulation
is the underlying mechanismʼ [5]. An expert committee
convened by the US Department of Defense called for
more research into the mechanism of action of TXA in
trauma patients [6].
In response to these concerns, we conducted further
analyses of the CRASH-2 trial data to examine the tim-
ing of the effect of TXA on mortality. It is generally ac-
cepted that deaths due to bleeding occur soon after thetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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sortium (BARC), which was established to provide a
standard definition of bleeding for use in clinical trials,
noted that ? the time interval from the bleeding event to
the death should be considered with respect to likely
causalityʼ, although they do not specify a particular
interval [8]. The MATTERS investigators argued that
beyond 48 h, bleeding is less likely to be the primary
cause of death. We hypothesised that if TXA improves
survival by reducing bleeding, its effect should be great-
est on the day of the injury. On the other hand, if it im-
proves survival by reducing inflammation its effect
should be most apparent in subsequent days.
Methods
Study design and patients
The CRASH-2 trial was a randomised placebo-controlled
trial of the effect of TXA on death and vascular occlusive
events in adult trauma patients with, or at risk of, signifi-
cant bleeding, and who were within 8 h of their injury. Pa-
tients were randomly assigned to receive TXA (loading
dose 1 g over 10 minutes followed by an infusion of 1 g
over 8 h) or matching placebo. The primary outcome was
death in hospital within 4 weeks of injury. Cause of death
was described using the following categories: bleeding,
vascular occlusion (myocardial infarction, stroke, and pul-
monary embolism), multi-organ failure, head injury, and
other. Follow-up data were available for 99.6% of patients.
The trial was conducted in 274 hospitals in 40 countries.
A detailed description of the rationale, design, methods
and results of the trial has been published previously [1].
Analysis
Both per-protocol and intention-to-treat analyses were
conducted. The effect of TXA on mortality was assessed
using hazard ratios (HR), which give the ratio of the
probability of death in the TXA and placebo group at a
given time point, among patients surviving to that time
point. It represents the instantaneous risk of death for
an individual who has survived to that particular time
point. We calculated HR for all-cause mortality, death
due to bleeding and for non-bleeding deaths, on the day
of the injury and for the subsequent four days. We also
conducted analyses stratified by time from injury to the
initiation of TXA treatment (≤3 h or >3 h). Precision
was quantified using 95% CI.
To give a visual representation of the results, we pre-
pared a heat map of the smoothed HR. We stratified pa-
tients into one-hour intervals by time from injury to
treatment and estimated HR for all-cause mortality for
each stratum over the first 5 days. We plotted these HR in
a two-dimensional coloured heat map of nine by five
cells. To reduce the impact of random variability, we
smoothed the HR using a simple moving average method.The smoothed HR was a double-weighted average of itself
and the neighbouring HR. The two weights were: 1) the
inverse of the variance of the HR and 2) the inverse of the
distance between the smoothed HR and the neighbouring
HR. Distance was defined as 1 for the HR being smoothed,
with +1 being added for each day and hour of separation
up to a maximum of 3 units (see Additional file 1 for an
example of distances).
The trial was considered and approved by the relevant
ethics committees in all participating hospitals (see
Additional file 2). Consent procedures at participating
hospitals were established by local regulation and the
appropriate ethics committees. Informed consent was
obtained from patients if physical and mental capacity
allowed. If patients could not give consent, proxy con-
sent was obtained from a relative or representative. If a
proxy was unavailable, then if permitted by local regula-
tion, consent was deferred or waived. When consent
was deferred or given by a proxy, the patient was in-
formed about the trial as soon as possible and consent
obtained for the use of the data collected.
Results
Of the 20,211 patients who were randomly allocated to re-
ceive TXA or placebo, primary outcome data were avail-
able for 20,127 patients (99.6%) (10,060 allocated to TXA
and 10,067 to placebo). There were 3,076 deaths (15.3%).
Figure 1 shows cause of death by day since injury. On the
day of the injury, there were 990 (32.2%) deaths, 587
(59%) of which were due to bleeding. A total 19,944 pa-
tients (99.1%) were known to have received a loading dose
of TXA or placebo and 3,021 of these patients died. The
following results are based on patients who received the
loading dose of TXA or placebo (per protocol analysis).
The intention-to-treat analyses were essentially the same.
There was a significant reduction in the hazard of
death from all causes in TXA treated patients on the day
of the injury (HR = 0.83, 95% CI 0.73, 0.93). Thereafter,
there was no significant reduction in the hazard of death
from all causes (Table 1). Figure 2 shows a heat map of
the smoothed HR, stratified by time from injury to treat-
ment and day of death.
Among those treated within 3 h of injury, there was a
22% reduction in the hazard of death from all causes on
the day of the injury (HR = 0.78, 95% CI 0.68, 0.90).
There was no reduction in the hazard of death from all
causes on the day of the injury among those treated after
3 hours (HR = 1.02, 95% CI 0.76, 1.36).
There was a significant reduction in the hazard of death
due to bleeding in TXA treated patients on the day of the
injury (HR = 0.80, 95% CI 0.68, 0.94). Thereafter, there was
no significant reduction in the hazard of death due to
bleeding (Table 1). There were no significant reductions in
the hazard of death from causes other than bleeding.
Figure 1 Cause of death by day since injury.
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non-bleeding deaths, stratified by the time interval from
the injury to randomisation. For patients treated within
3 h of injury, the hazard of death due to bleeding was
significantly reduced with TXA on the day of the injury
(day 0), the following day (day 1) and on day 3. There
were no significant reductions in the hazard of non-
bleeding deaths.
Discussion
The effect of TXA on mortality is greatest on the day of
the injury, when TXA reduces the risk of death from allTable 1 Hazard ratios (95% CI) of the effect of tranexamic
acid on all-cause mortality, bleeding and non-bleeding
deaths by day since injury
Days since injury All-cause Bleeding Non-bleeding
0 0.83 (0.73, 0.93) 0.80 (0.68, 0.94) 0.87 (0.71, 1.06)
1 0.91 (0.79, 1.04) 0.89 (0.72, 1.11) 0.92 (0.76, 1.11)
2 0.96 (0.77, 1.19) 1.17 (0.74, 1.86) 0.91 (0.71, 1.16)
3 1.01 (0.76, 1.34) 0.66 (0.32, 1.37) 1.09 (0.80, 1.48)
4 0.96 (0.70, 1.36) 0.77 (0.29, 2.06) 1.01 (0.71, 1.43)causes by about 20%. This survival benefit is only evi-
dent in patients in whom treatment is initiated within
3 h of injury. Thereafter, early TXA treatment has a
smaller effect on all-cause mortality, although a reduc-
tion in the hazard of death due to bleeding is evident for
several days. Our results suggest that there is a short
time interval during which TXA administration can pre-
vent exsanguination and that urgent treatment is there-
fore essential.
Whilst the benefit of early TXA treatment is greatest
on the day of injury, the adverse effect of late adminis-
tration manifests as an increased risk of death due to
bleeding over subsequent days [2]. We have previously
postulated that late initiation of TXA treatment may in-
crease the risk of thrombotic disseminated intravascular
coagulation (DIC) [9,10]. By inhibiting fibrinolysis, TXA
might increase the risk of DIC. Although the underlying
pathology in DIC is thrombosis, due to the consumption
of coagulation factors DIC often manifests as bleeding.
Among patients in whom treatment is initiated beyond
3 h of the injury, deaths apparently due to bleeding may
have been due to thrombotic DIC.
The strength of this analysis is that it is based on data
from a randomised controlled trial with over 20,000
Figure 2 Heat map of smoothed hazard ratios (HR) stratified by time to treatment and day of death.
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this study has considerable statistical power to examine
the temporal effects of TXA administration. Neverthe-
less, because a large proportion of the deaths occurred
in the first 48 h after injury, the subsequent HR are im-
precise with wide confidence intervals. A further weak-
ness is that these analyses were not pre-specified in the
trial protocol with the attendant risk that random pat-
terns in the data may have been over interpreted. These
results should therefore be interpreted cautiously and in
the context of other relevant research.
The hypothesis that TXA has beneficial mechanisms
other than haemostasis was suggested by the MATTERS
investigators on the basis that there was ? no difference in
mortality between the TXA and no TXA groups until
the 48-hour pointʼ. However, the MATTERS data show
a 23% relative reduction in all-cause mortality at 24 h
(9.6% versus 12.4%; P = 0.2) [4]. Although this reduction
was not statistically significant, it is not possible from
these data to exclude a possible effect on mortality; ra-
ther, only that such a statistically significant effect wasTable 2 Hazard ratios (95% CI) of the effect of tranexamic aci
deaths by day since injury and time from injury to treatment
Days since injury Time to treatment ≤3 h
All-cause Bleeding Non- ble
0 0.78 (0.68, 0.90) 0.72 (0.60, 0.86) 0.89 (0.71
1 0.86 (0.72, 1.02) 0.72 (0.55, 0.94) 0.98 (0.78
2 0.86 (0.65, 1.13) 1.01 (0.58, 1.77) 0.82 (0.59
3 0.95 (0.66, 1.37) 0.26 (0.09, 0.78) 1.20 (0.80
4 0.94 (0.61, 1.45) 0.64 (0.18, 2.28) 0.99 (0.63not observed. With much larger patient numbers, we
found a similar reduction in early mortality with TXA
that was highly statistically significant.
The lack of any apparent effect of TXA administration
on the receipt of blood transfusion has also contributed to
the debate about its mechanism of action. However, there
are several possible reasons why TXA did not reduce the
receipt of blood transfusion in the CRASH-2 trial. First,
much of the blood loss in trauma patients occurs before
hospital admission and therefore before TXA administra-
tion. Some of the transfusions that patients received in
hospital would have been in response to this early bleeding
and could not have been influenced by TXA. Second, be-
cause TXA reduced mortality, more TXA-treated patients
had the opportunity to be transfused. Third, any effect of
TXA on blood transfusion may have been diluted by
transfusions given later during the hospital stay, for ex-
ample transfusions given during orthopaedic surgery. Fi-
nally, accurate estimation of blood loss is difficult in
trauma patients and so the amount of blood transfused
might not indicate the amount of blood lost.d on all-cause mortality, bleeding and non-bleeding
Time to treatment >3 h
eding All-cause Bleeding Non- bleeding
, 1.11) 1.02 (0.76, 1.36) 1.28 (0.85, 1.93) 0.79 (0.51, 1.22)
, 1.23) 1.02 (0.80, 1.31) 1.47 (0.97, 2.21) 0.81 (0.59, 1.13)
, 1.12) 1.16 (0.81, 1.66) 1.61 (0.70, 3.70) 1.08 (0.72, 1.60)
, 1.81) 1.11 (0.73, 1.71) 2.76 (0.73, 10.39) 0.98 (0.62, 1.55)
, 1.57) 1.04 (0.62, 1.75) 1.04 (0.21, 5.13) 1.04 (0.60, 1.80)
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Because coagulation, fibrinolysis and inflammation are
closely interwoven pathophysiological responses, at-
tempts to draw a clear distinction between the anti-
fibrinolytic and anti-inflammatory effects of TXA may
be inappropriate [11]. It would also be inappropriate to
conclude that an effect on deaths prior to a specified
number of hours or days necessarily implies that TXA
works by reducing bleeding as opposed to reducing in-
flammation. Nevertheless, the finding that the effect of
TXA is greatest on the day of the injury and for deaths
due to bleeding supports the hypothesis that TXA im-
proves survival by reducing bleeding. The large benefit
from early administration and the absence of benefit
from late administration also supports this proposition.
This view is consistent with the pharmacology of TXA
and with results of clinical trials of TXA in elective sur-
gery in which blood loss can be accurately quantified
[12,13]. Although the data presented here do not ex-
clude the possibility TXA might have clinically import-
ant anti-inflammatory effects, at present there is no
evidence from randomised controlled trials that TXA re-
duces inflammation in trauma patients, although trials
in progress will provide further information [7].
Key messages
 To investigate the mechanism of action of TXA in
bleeding trauma patients we examined the timing of
its effect on mortality
 We hypothesised that if TXA reduces mortality by
decreasing bleeding, its effect should be greatest on
the day of the injury, but if it reduces mortality via
an anti-inflammatory mechanism, its effect should
be greater over subsequent days
 We found that the effect of TXA on mortality is
greatest on the day of the injury, when early TXA
treatment reduces the risk of death from all causes
by about 20% and death due to bleeding by about
30%. Our results support the hypothesis that TXA
improves survival by reducing bleeding
 There is a short time-window during which TXA
administration can prevent exsanguination; urgent
treatment may therefore be essential
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